December 8, 2025BloodOpen Access

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

View Full Paper

Ask AI

Bookmark

Anemia response achieved in 19 of 40 myelofibrosis patients treated with gecacitinib, showcasing a significant reduction in ferritin and improvement in hemoglobin levels.
Analysis revealed a median change in ferritin of -109.5 ng/ml within 24 weeks, indicating dynamic ferritin changes alongside hemoglobin response.
Post-hoc analysis utilized multivariate logistic regression and found that JAK2 mutation status was a key predictor of anemia response.
Patients who responded had higher spleen volume reduction and longer treatment duration compared to non-responders, highlighting treatment efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Post-hoc analysis reveals hemoglobin levels and ferritin dynamics predict anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7a1 https://doi.org/10.1182/blood-2025-2029

View Full Paper

Ask AI

Bookmark

Implication

Post-hoc analysis reveals hemoglobin levels and ferritin dynamics predict anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib.

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Key Points

Discussion

Implication

Cite This Study

Ferritin change and predictors of anemia response in ruxolitinib-intolerant myelofibrosis patients treated with gecacitinib

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading